Sichuan Cancer Hospital and Institute

Chengdu, Sichuan 610041

2 studies enrolling now · 5 studies all time

What they study most

Advanced Solid Tumor, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Local Advanced Hepatocellular Carcinoma, Locally Advanced and Metastatic Solid Tumors, Metastatic Hepatocellular Carcinoma, NSCLC, Non-small Cell Lung Cancer

Studies at this site

• A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
• An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors — Recruiting now
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma — Running, not enrolling
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer — Stopped early
• Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors — Completed